Membrane‐Based Approach for the Downstream Processing of Influenza Virus‐Like Particles

2019 ◽  
Vol 14 (8) ◽  
pp. 1800570 ◽  
Author(s):  
Sofia B. Carvalho ◽  
Ricardo J. S. Silva ◽  
Mafalda G. Moleirinho ◽  
Bárbara Cunha ◽  
Ana S. Moreira ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Downstream Processing ◽  
Virus Like Particles

Highly immunogenic influenza virus-like particles containing B-cell-activating factor (BAFF) for multi-subtype vaccine development

2019 ◽  
Vol 164 ◽  
pp. 12-22 ◽  
Author(s):  
Jo-Yu Hong ◽  
Ting-Hsuan Chen ◽  
Yu-Jou Chen ◽  
Chia-Chyi Liu ◽  
Jia-Tsrong Jan ◽  
...  
Keyword(s):  
Influenza Virus ◽  
B Cell ◽  
Vaccine Development ◽  
Virus Like Particles ◽  
B Cell Activating Factor

scholarly journals Influenza virus-like particles produced by transient expression inNicotiana benthamianainduce a protective immune response against a lethal viral challenge in mice

2008 ◽  
Vol 6 (9) ◽  
pp. 930-940 ◽  
Author(s):  
Marc-André D’Aoust ◽  
Pierre-Olivier Lavoie ◽  
Manon M.-J. Couture ◽  
Sonia Trépanier ◽  
Jean-Martin Guay ◽  
...  
Keyword(s):  
Immune Response ◽  
Influenza Virus ◽  
Transient Expression ◽  
Protective Immune Response ◽  
Viral Challenge ◽  
Virus Like Particles

Induction of protective immune response to intranasal administration of influenza virus‐like particles in a mouse model

2019 ◽  
Vol 234 (9) ◽  
pp. 16643-16652 ◽  
Author(s):  
Mohsen Keshavarz ◽  
Haideh Namdari ◽  
Yaser Arjeini ◽  
Hamed Mirzaei ◽  
Vahid Salimi ◽  
...  
Keyword(s):  
Immune Response ◽  
Influenza Virus ◽  
Mouse Model ◽  
Intranasal Administration ◽  
Protective Immune Response ◽  
Virus Like Particles

scholarly journals The Lack of an Inherent Membrane Targeting Signal Is Responsible for the Failure of the Matrix (M1) Protein of Influenza A Virus To Bud into Virus-Like Particles

2010 ◽  
Vol 84 (9) ◽  
pp. 4673-4681 ◽  
Author(s):  
Dan Wang ◽  
Aaron Harmon ◽  
Jing Jin ◽  
David H. Francis ◽  
Jane Christopher-Hennings ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Plasma Membrane ◽  
Influenza A Virus ◽  
Influenza A ◽  
Envelope Proteins ◽  
Viral Envelope ◽  
Membrane Targeting ◽  
Virus Like Particles ◽  
The Matrix ◽  
Targeting Signal

ABSTRACT The matrix protein (M1) of influenza A virus is generally viewed as a key orchestrator in the release of influenza virions from the plasma membrane during infection. In contrast to this model, recent studies have indicated that influenza virus requires expression of the envelope proteins for budding of intracellular M1 into virus particles. Here we explored the mechanisms that control M1 budding. Similarly to previous studies, we found that M1 by itself fails to form virus-like-particles (VLPs). We further demonstrated that M1, in the absence of other viral proteins, was preferentially targeted to the nucleus/perinuclear region rather than to the plasma membrane, where influenza virions bud. Remarkably, we showed that a 10-residue membrane targeting peptide from either the Fyn or Lck oncoprotein appended to M1 at the N terminus redirected M1 to the plasma membrane and allowed M1 particle budding without additional viral envelope proteins. To further identify a functional link between plasma membrane targeting and VLP formation, we took advantage of the fact that M1 can interact with M2, unless the cytoplasmic tail is absent. Notably, native M2 but not mutant M2 effectively targeted M1 to the plasma membrane and produced extracellular M1 VLPs. Our results suggest that influenza virus M1 may not possess an inherent membrane targeting signal. Thus, the lack of efficient plasma membrane targeting is responsible for the failure of M1 in budding. This study highlights the fact that interactions of M1 with viral envelope proteins are essential to direct M1 to the plasma membrane for influenza virus particle release.

scholarly journals Influenza virus-like particles coated onto microneedles can elicit stimulatory effects on Langerhans cells in human skin

Vaccine ◽  
2010 ◽  
Vol 28 (37) ◽  
pp. 6104-6113 ◽  
Author(s):  
Marc Pearton ◽  
Sang-Moo Kang ◽  
Jae-Min Song ◽  
Yeu-Chun Kim ◽  
Fu-Shi Quan ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Human Skin ◽  
Langerhans Cells ◽  
Virus Like Particles

scholarly journals Intranasal Vaccination with 1918 Influenza Virus-Like Particles Protects Mice and Ferrets from Lethal 1918 and H5N1 Influenza Virus Challenge

2009 ◽  
Vol 83 (11) ◽  
pp. 5726-5734 ◽  
Author(s):  
Lucy A. Perrone ◽  
Attiya Ahmad ◽  
Vic Veguilla ◽  
Xiuhua Lu ◽  
Gale Smith ◽  
...  
Keyword(s):  
Influenza Virus ◽  
H5n1 Virus ◽  
Influenza Pandemic ◽  
Human Case ◽  
Lethal Challenge ◽  
Virus Like Particles ◽  
Virus Challenge ◽  
H5n1 Influenza ◽  
Pandemic Virus ◽  
Homologous Virus

ABSTRACT Influenza vaccines capable of inducing cross-reactive or heterotypic immunity could be an important first line of prevention against a novel subtype virus. Influenza virus-like particles (VLPs) displaying functional viral proteins are effective vaccines against replication-competent homologous virus, but their ability to induce heterotypic immunity has not been adequately tested. To measure VLP vaccine efficacy against a known influenza pandemic virus, recombinant VLPs were generated from structural proteins of the 1918 H1N1 virus. Mucosal and traditional parenteral administrations of H1N1 VLPs were compared for the ability to protect against the reconstructed 1918 virus and a highly pathogenic avian H5N1 virus isolated from a fatal human case. Mice that received two intranasal immunizations of H1N1 VLPs were largely protected against a lethal challenge with both the 1918 virus and the H5N1 virus. In contrast, mice that received two intramuscular immunizations of 1918 VLPs were only protected against a homologous virus challenge. Mucosal vaccination of mice with 1918 VLPs induced higher levels of cross-reactive immunoglobulin G (IgG) and IgA antibodies than did parenteral vaccination. Similarly, ferrets mucosally vaccinated with 1918 VLPs completely survived a lethal challenge with the H5N1 virus, while only a 50% survival rate was observed in parenterally vaccinated animals. These results suggest a strategy of VLP vaccination against a pandemic virus and one that stimulates heterotypic immunity against an influenza virus strain with threatening pandemic potential.

Sign in / Sign up

Export Citation Format

Share Document